ClinicalTrials.gg

Program

trastuzumab pamirtecan

Also written as “DB-1303/BNT323”, “BNT323/DB-1303” and “BNT323”.

Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms · Neoplasm Metastasis, led by 2 companies.

Furthest: phase 3, since Aug 25, 20235 company-led studies, 5 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
DualityBio33 open or runningphase 3since Aug 25, 2023Nov 11, 2021Aug 2027phase 2 · NCT05150691
BioNTech22 open or runningphase 3since Mar 25, 2024Mar 25, 2024Mar 2028phase 3 · NCT06340568

Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2021First study: phase 2 study in Neoplasm MetastasisNew to DualityBioDualityBio · NCT05150691 · 796 planned · United States, Australia, China and more
  2. Aug 25, 2023Phase 3 study in Breast NeoplasmsDualityBio · NCT06018337 · 541 enrolled · United States, Argentina, Australia and more
  3. Jan 5, 2024Phase 3 study in Breast NeoplasmsDualityBio · NCT06265428 · 228 enrolled · China
  4. Mar 25, 2024BioNTech’s first study: phase 3 study in Endometrial NeoplasmsNew to BioNTechBioNTech · NCT06340568 · 480 planned · United States, Argentina, Australia and more
  5. Feb 10, 2025Phase 2 study in Breast NeoplasmsBioNTech · NCT06827236 · 380 planned · United States, Australia, Canada and more

Ahead

  1. Aug 2027Primary completion: phase 2 study in Neoplasm MetastasisDualityBio · NCT05150691
  2. Dec 2027Primary completion: phase 3 study in Breast NeoplasmsDualityBio · NCT06265428
  3. Mar 2028Primary completion: phase 3 study in Endometrial NeoplasmsBioNTech · NCT06340568
  4. Aug 2029Primary completion: phase 2 study in Breast NeoplasmsBioNTech · NCT06827236

TargetBeta

ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06827236Breast Neoplasms · United States, Australia, Canada and more2RecruitingBioNTechAug 2029380
NCT06340568Endometrial Neoplasms · United States, Argentina, Australia and more3RecruitingBioNTechMar 2028480
NCT06265428Breast Neoplasms · China3Active, not recruitingDualityBioDec 2027228
NCT06018337Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingDualityBioAug 12, 2026541
NCT05150691Neoplasm Metastasis · United States, Australia, China and more2RecruitingDualityBioAug 2027796

How it is read

Names in the registry

  • “DB-1303/BNT323”, 3 entries
  • “BNT323/DB-1303”, 1 entry
  • “BNT323”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.